Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 5 | 1 | — | — | 8 |
Lung neoplasms | D008175 | — | C34.90 | 1 | 4 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | — | 3 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | 2 | 2 | — | — | — | 2 |
Pancreatic ductal carcinoma | D021441 | — | — | — | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Oleclumab |
INN | oleclumab |
Description | Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990016 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 5CRY01URYQ (ChemIDplus, GSRS) |